ACOG Practice Bulletin, No 15.  Obstet Gynecol 2000;95:end of issue 4.

Apter D, Borsos A, Baumgartner W, et al.  Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.  Eur Contracept Reprod Health Care 2003;8:37-51.

Atmaca M, Kumru S, Tezcan E.  Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 2003;18:191-5.

Backstrom T, Andersson A, Andree L, et al.  Pathogenesis in menstrual cycle-linked CNS disorders.  Ann N Y Acad Sci 2003;1007:42-53.

Bailey JW, Cohen LS.  Prevalence of mood and anxiety disorders in women who seek treatment for premenstrual syndrome.  J Womens Health Gend Based Med 1999;8:1181-4.

Borenstein JE, Dean BB, Endicott J, et al.  Health and economic impact of the premenstrual syndrome. J Reprod Med 2003;48:515-24. 

Borenstein J, Chiou CF, Dean B, et al.  Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005;47:26-33.

Brown C, Ling F, Wan J.  A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.  J Reprod Med 2002;47:14-22.

Clayton AH, Keller AE, Leslie C, Evans W.  Exploratory study of premenstrual symptoms and serotonin variability.  Arch Of Women’s Mental Health 2006;9:51-7.

Cohen LS, Miner C, Brown EW.  Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled clinical trial using computerized diaries.  Obstet Gynecol 2002;100:435-44.

Cohen LS, Soares CN, Yonkers KA.  Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial.  Psychosom Med 2004;66:707-13.

Endicott J, Nee J, Harrison W.  Daily Record of Severity of Problems (DRSP): reliability and validity.  Arch Womens Mental Health 2006;9:41-9.

Facchinetti F, Genazzani AD, Martignoni E, et al.  Neuroendocrine changes in luteal function in patients with premenstrual syndrome.  J Clin Endocrinol Metab 1993;76:1123-7.

Ferguson JM.  SSRI antidepressant medications: Adverse effects and tolerability.  Prim Care Companion J Clin Psychiatry 2001;3:22-7.

Freeman EW, Kroll R, Rapkin A, et al.  Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.  J Womens Health Gend Based Med 2001;10:561-9.

Freeman EW, Stout AL, Endicott J, Spiers P.  Treatment of premenstrual syndrome with a carbohydrate-rich beverage.  Int J Gynaecol Obstet 2002;77:253-4.

Gottheil M, Steinberg R, Granger L.  An exploration of clinicians’ diagnostic approaches to premenstrual symtomatology.  Can J Behav Sci 1999;31:254-62.

Graze KK, Nee J, Endicott J.  Premenstrual depression predicts future major depressive disorder.  Acta Psychiatr Scand 1990;81:201-5.

Halbreich U, Borenstein J, Pearlstein T, Kahn LS.  The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD).  Psychoneuroendocrinology 2003;28(suppl 3):1-23.

Halbreich U, Bergeron R, Yonkers KA, et al.  Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder.  Obstet Gynecol 2002;100:1219-29.

Hunter JS, Ussher JM, Browne SJ, et al.  A randomized comparison of psychological (cognitive behavioral therapy), medical therapy (fluoxetine), and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002;23:193-9.

Hylan TR, Sundell K, Judge R.  The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: Experience from the United States, United Kingdom, and France.  J Womens Health Gend Based Med 1999;8:1043-52.

Joffe H, Cohen LS, Harlow BL: Impact of oral contraceptive pill use on premenstrual mood, clumsiness, food craving and other symptoms.  J Psychosom Res 1993;37:195-202.

Kendler KS, Karkowski LM, Corey LA, Neale MC.  Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression.  Am J Psychiatry 1998;155:1234-40.

Kirkby RJ.  Changes in premenstrual symptoms and irrational thinking following cognitive-behavioral coping skills training.  J Consult Clin Psychol 1994;62:1026-32.

Kraemer GR, Kraemer RR.  Premenstrual syndrome: diagnosis and treatment experiences.  J Womens Health 1998;7:893-907.

Ling FW.  Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices.  J Clin Psychiatry 2000;61:9-16.

Mortola JF, Girton L, Beck L, Yen SS.  Diagnosis of premenstrual syndrome by a single, prospective, and reliable instrument:  The Calendar of Premenstrual Experiences.  Obstet Gynecol 1990;76:302-7.

O’Brien PM, Craven D, Selby C, Symonds EM.  Treatment of premenstrual syndrome by spironolactone.  Br J Obstet Gynaecol 1979;86:142-7.

Pearlstein TB, Bellew KM, Endicott J, Steiner M.  Paroxetine controlled release for premenstrual dysphoric disorder: Remission analysis following a randomized, double-blind, placebo-controlled trial.  Prim Care Companion J Clin Psychiatry 2005;7:53-60.

Pearlstein TB, Frank E, Rivera-Tovar A, et al.  Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder.  J Affect Disord 1990;20:129-34.

Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA.  Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.  Contraception 2005;72:414-42

Premenstrual dysphoric disorder.  American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision.  Washington, DC: American Psychiatric Association 2000:771-4

Prilepskaya VN, Ledina AV, Tagiyeva AV, Revazova FS.  Vitex agnus castus: successful treatment of moderate to severe premenstrual syndrome. Maturitas 2006;55(suppl 1):s55-63.

Rapkin AJ, Morgan M, Goldman L, et al.  Progesterone metabolite allopregnanolone in women with premenstrual syndrome.  Obstet Gynecol 1997;90:709-14.

Rapkin AJ, Edelmuth E, Chang LC, et al.  Whole-blood serotonin in premenstrual syndrome.  Obstet Gynecol 1987;70:533-7.

Sangthawan M, Taneepanichskul S.  A comparative study of monophasic oral contraceptives containing either drospirenone 3mp or levonorgestrel 150 microg on prementstrual symptoms.  Contraception 2005;71:1-7.

Sayegh R, Schiff I, Wurtman J, et al.  The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome.  Obstet Gynecol 1995;86:520-28.

Schellenberg R.  Treatment for premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study.  BMJ 2001;322:134-7.

Schmidt PJ, Nieman LK, Danaceau MA, et al.  Differential behavioral effects of gonadal steroids in women with and in those without premenstrual symptoms.  N Engl J Med 1998;338:209-16.

Steiner M, Steinberg S, Stewart D, et al.  Fluoxetine in the treatment of premenstrual dysphoria.  Canadian Flueoxetine/Premenstrual Dysphoria Collaborative Study Group.  N Engl J Med 1995;332:1529-34.

Steiner M, Hirschberg AL, Bergeron R, et al.  Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder.  Am J Obstet Gynecol 2005;193:352-60.

Sulak PJ, Scow RD, Preece C, et al.  Hormone withdrawal symptoms in oral contraceptive users.  Obstet Gynecol 2000;95:261-6.

Sundstrom-Poromaa I, Bixo M, Bjorn I, Nordh O.  Compliance to antidepressant drug therapy for the treatment for premenstrual syndrome.  J Psychosom Obstet Gynaecol 2000;21:205-11.

Sundstrom I, Nyberg S, Bixo M, et al.  Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen.  Acta Obstet Gynecol Scand 1999;78:891-9.

Thys-Jacobs S, Starkey P, Bernstein D, Tian J.  Calcium carbonate and the premenstrual syndrome: Effects on premenstrual and menstrual symptoms:  Premenstrual Syndrome Study Group.  Am J Obstet Gynecol 1998;179:444-52.

U.S. Dept of Health and Human Services: Dietary Guidelines for Americans, 2005. Available at www.healthierus.gov/dietaryguidelines.  Accessed January 8, 2007.

Wang M, Hammarback S, Lindhe BA, Backstrom T.  Treatment of premenstrual syndrome by spironolactone: A double-blind, placebo-controlled study.  Acta Obstet Gynecol Scand 1995;74:803-8.

Wyatt KM, Dimmock PW, Jones PW, Shaughn-O’Brien PM.  Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: Systematic review. BMJ 1999;318:1375-81.

Wyatt KM, Dimmock PW, O’Brien PM.  Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Rev 2002:CD001396.

Yonkers KA, Brown C, Pearlstein TB, et al.  Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.  Obstet Gynecol 2005;106:492-501.

Yonkers KA, Halbreich U, Freeman E, et al.  Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment.  A randomized controlled trial: Sertraline Premenstrual Dysphoric Collaborative Study Group.  JAMA 1997;278:983-8.